药品综合评价方法研究进展

doi:10.19803/j.1672-8629.2022.07.25

中国药物警戒 ›› 2022, Vol. 19 ›› Issue (7): 803-806.
DOI: 10.19803/j.1672-8629.2022.07.25

药品综合评价方法研究进展

杨萍^1,2, 鲁松^1,2, 董宪喆^1#, 张兰^1,*

¹首都医科大学宣武医院药学部,北京 100053;
²遵义医科大学药学院,贵州遵义 563000

收稿日期:2020-12-02 出版日期:2022-07-15 发布日期:2022-07-12
通讯作者: ^*张兰,女,博士,主任药师,医院药学。E-mail：xwzhanglan@126.com;^#为共同通信作者。
作者简介:杨萍,女,硕士,临床药学。
基金资助:
重大新药创制国家科技重大专项2017年度（2017ZX09101-001-002-044）; 首都科技领军人才培养工程（Z191100006119017）; 北京市医院管理中心“登峰”计划专项（DFL20190803）; 首都医科大学宣武医院“汇智”人才工程学者计划-培育计划（领军人才）

Research progress in comprehensive evaluation methods of drugs

YANG Ping^1,2, LU Song^1,2, DONG Xianzhe^1#, ZHANG Lan^1,*

¹Department of Pharmacy, Xuanwu Hospital, Capital Medical University, Beijing 100053, China;
²School of Pharmacy, Zunyi Medical University, Zunyi Guizhou 563000, China

Received:2020-12-02 Online:2022-07-15 Published:2022-07-12

摘要/Abstract

摘要： 随着医疗改革的深入,国家和医疗机构对精细化药事管理及患者对精准化药学服务的需求,药品综合评价势在必行。科学规范的药品综合评价及其结果的应用,将为国家药品相关目录和技术规范的修订、医疗机构药品临床合理使用和规范管理等提供科学依据。本文通过检索药品综合评价方法相关文献,对国内外药品综合评价的现状和方法进行综述,探讨不同评价方法的特点和关键技术环节,为我国规范化药品综合评价体系的建设和完善提供参考。

关键词: 药品综合评价, 药品评价方法, 药学服务

Abstract: With the deepening of health care reforms, amid refined pharmaceutical management by the state and medical institutions and along with patients' demand for precise pharmaceutical services, comprehensive drug evaluation has become imperative. The scientific and standardized comprehensive evaluation of drugs and the application of the results will provide data for the revision of the national drug-related catalogs and technical specifications, the rational clinical use of drugs in medical institutions, and for standardized management. By searching the literature related to comprehensive drug evaluation methods, the methods currently available at home and abroad are reviewed, and the characteristics and key elements of different methods are discussed so as to provide reference for the construction and improvement of a standardized comprehensive drug evaluation system in China.

Key words: comprehensive evaluation of drug, evaluation method for drug, pharmaceutical services

中图分类号:

R954

杨萍, 鲁松, 董宪喆, 张兰. 药品综合评价方法研究进展[J]. 中国药物警戒, 2022, 19(7): 803-806.

YANG Ping, LU Song, DONG Xianzhe, ZHANG Lan. Research progress in comprehensive evaluation methods of drugs[J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 803-806.

参考文献

[1] TAN ZX, XU P.Establishment of comprehensive drug evaluation system in China needs to be completed and further improvement[J]. Drug Evaluation(药品评价), 2011, 8(18): 4-5.
[2] ZHANG GJ, CHU XY, TIAN YJ, et al.Implication of EU pharma-covigilance system to China[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2015, 12(10): 593-596.
[3] LIU J, LI CL, GUO LH, et al.Research on system of post-marketing evaluation in Japan[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2017, 14(3): 158-160.
[4] LIU PY.Brief introduction to the post-marketing evaluation system of foreign drugs[J]. Shanghai Medical & Pharmaceutical Journal(上海医药), 2004, 12(5): 208-210.
[5] HE W.Concepts and types of re-evaluation of post-marketing drugs in China[J]. Central South Pharmacy(中南药学), 2015, 13(7): 780-782.
[6] China Drug Comprehensive Evaluation Guidelines Project Team. Guideline for comprehensive evaluation of medicine in China (2nd edition)[J].Drug Evaluation(药品评价), 2015, 12(8): 6.
[7] National Health Commission of the People's Republic of China.Notice on Carrying out Drug Use Monitoring and Clinical Comprehensive Evaluation[EB/OL].(2019-04-09)[2020-12-01]. http://www.nhc.gov.cn/cms-search/xxgk/getManuscriptXxgk.htm?id=31149bb1845e4c019a04f30c0d69c2c9.
[8] TIAN L, GUAN X, MA AX.Systematic comparison of randomized controlled trial study and observational study[J]. China Pharmacy(中国药房), 2018, 29(4): 493-496.
[9] HAN M, CHEN W, CAO HJ, et al.One of comparative effectiveness research: cohort study design[J]. Modern Chinese Clinical Medicine(现代中医临床), 2015, 22(3): 20-23.
[10] ZHOU JM.Improving national essential drug related work and pushing the development and implementation of national drug policies[J]. Chinese Pharmaceutical Affairs(中国药事), 2005(3): 3-5.
[11] TIAN L, FU LY, MA AX.Understanding of economic re-evaluation of Chinese drugs after market[J]. Herald of Medicine(医药导报), 2020, 39(6): 884-886.
[12] LIU GE.China Pharmacoeconomic Evaluation Guidelines (2020))(中国药物经济学评价指南(2020))[M]. Beijing: China Market Press, 2020.
[13] WU JH.Guideline for comprehensive evaluation of medicine in China (2nd edition) chapter 6 guidelines for economic evaluation of clinical drugs[J]. Drug Evaluation(药品评价), 2015, 12(8): 16-19.
[14] SHI XY, ZHAO R, LI F, et al.Reflections on the establishment of clinical comprehensive evaluation mechanism for drugs in China[J]. China Pharmacy(中国药房), 2020, 31(23): 2828-2833.
[15] JIA LL, MENG Y, LIU YW, et al.Evidence-based comprehensive pediatric drug evaluation involved with analytic hierarchy process[J]. Chinese Journal of Pharmacoepidemiology(药物流行病学杂志), 2016, 25(10): 601-605.
[16] LIU Q, ZHANG SY, LI HY, et al.Exploration of evidence-based and pharmacoeconomics theory applied in China essential medicine List[J]. Chinese Journal of Drug Evaluation(中国药物评价), 2016, 33(5): 452-456.
[17] SHI FH, GU ZC, CUI M.Application of delphi method in pharm-acy[J]. China Pharmacist(中国药师), 2016, 19(5): 985-987.
[18] SUN ZS.Drug evaluation heavy as Taishan[J]. Drug Evaluation(药品评价), 2010, 7(2): 26-29.
[19] SUN X, TAN J, TANG L, et al.Revisiting real-world study[J]. Chinese Journal of Evidence-Based Medicine(中国循证医学杂志), 2017, 17(2): 126-130.
[20] SUN X, TAN J, TANG L, et al.Real world evidence: experience and lessons from China[J]. BMJ, 2018, 360(2): j5262.

药品综合评价方法研究进展

Research progress in comprehensive evaluation methods of drugs

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	王然, 冯欣, 杜博冉. 围孕期妊娠用药暴露风险评价与药学实践进展[J]. 中国药物警戒, 2023, 20(7): 836-840.
[2]	霍佩琼, 郑鹏, 苏振浩. 特殊或重大疾病零售药店开展药物警戒活动的思考[J]. 中国药物警戒, 2023, 20(4): 428-432.
[3]	吕锦涛, 张晓朦, 张冰, 姜皓, 林志健. 基于传统文献的围孕期妇女中药药物警戒挖掘与药学服务思考[J]. 中国药物警戒, 2022, 19(6): 585-590.
[4]	王晓芳, 张晓朦, 张冰, 林志健, 韦昌策. 基于儿科古文献的中药药物警戒思想与药学服务思考[J]. 中国药物警戒, 2022, 19(6): 591-594.
[5]	马冰冰, 张晓朦, 张冰, 林志健, 吕锦涛. 基于文献分析的老年人中成药合理用药与药学服务思考[J]. 中国药物警戒, 2022, 19(6): 595-599.
[6]	陈方方, 张红旭. 大剂量甲氨蝶呤治疗原发性中枢神经系统淋巴瘤的药学实践[J]. 中国药物警戒, 2022, 19(4): 446-449.
[7]	耿洪娇, 王连心, 谢雁鸣. 医疗机构开展中药药物警戒的思考[J]. 中国药物警戒, 2021, 18(6): 552-555.
[8]	萨日娜, 张冰, 林志健, 王晓芳, 张晓朦. 医疗机构药学服务中的中药药物警戒实践探讨[J]. 中国药物警戒, 2021, 18(5): 422-426.
[9]	韦元元, 栗芳, 陶小妹, 顾红燕. 呼吸科抗菌药物不良反应报告分析和防范措施[J]. 中国药物警戒, 2021, 18(11): 1083-1086.
[10]	蓝晓红, 周永刚, 臧菊香, 吴冬妮, 李祥, 许锐, 陈曙东, 于浩, 张烨. 临床药师主导的社区药学服务对老年患者他汀类药物治疗服务系统构建与评价的影响[J]. 中国药物警戒, 2020, 17(9): 594-599.
[11]	刘畅, 刘书亚, 张泰, 申红霞, 闫美兴. 药品不良反应信息化平台的建设与实践[J]. 中国药物警戒, 2020, 17(8): 471-473.
[12]	王明蕾, 王芳. 院外延伸药学服务对心梗患者PCI术后的预后及用药依从性的影响[J]. 中国药物警戒, 2018, 15(8): 485-488.
[13]	史秀梅,胡永领,梁艳丽,赵艳艳,王洁,谢士宁 . 肝功能损害患者临床药学服务模式的探索及效果评价[J]. 中国药物警戒, 2018, 15(5): 286-290.
[14]	潘凤珍,张平,张金梅. 院内外延伸药学服务对2型糖尿病患者治疗效果及不良反应发生率的影响[J]. 中国药物警戒, 2017, 14(12): 764-768.
[15]	张亚同, 赵明, 赵紫楠, 董凡, 胡欣. 中外药学服务文献计量学研究[J]. 中国药物警戒, 2016, 13(9): 540-542.